The prevalence of fimA genotypes of Porphyromonas gingivalis in patients with chronic periodontitis: A meta-analysis.

FimA is an important virulence factor of Porphyromonas gingivalis (P. gingivalis). According to its DNA sequence, the fimA genotype of P. gingivalis can be divided into six categories (I, Ib, Ⅱ, III, IV, V). The fimA gene may be a key factor in the diversity of virulence found in P. gingivalis. Moreover, the role fimA plays in the pathogenesis of P. gingivalis is closely associated with periodontitis, making it an important factor of study for disease prevention and treatment. In this study, the prevalence of fimA genotypes of P. gingivalis in patients with periodontal diseases was evaluated by meta-analysis. The Embase and PubMed databases were searched for articles from 1999 to 2019 using the following search terms: Porphyromonas gingivalis or P. gingivalis; periodontitis or chronic periodontal disease; fimA or fimA genotype. The reference lists of relevant published articles were searched manually. A total of 17 studies were included in this report. A statistical software package (Stata, version 11.0/mp, StataCorp) was utilized to calculate and analyze the P. gingivalis fimA genotypes for each combined incidence estimate. The pooled rates of fimA Ⅰ, fimA Ib, fimA Ⅱ, fimA Ⅲ, fimA Ⅳ and fimA Ⅴ genotypes of P. gingivalis were 8.4% (95% CI: 5.7-11.1), 11.7% (95% CI: 7.4-16), 42.9% (95% CI: 34.2-51.7), 6.5% (95% CI: 5.1-7.9), 17.8% (95% CI: 9.0-26.5), and 3.2% (95% CI: 1.6-4.9), respectively. This study showed that the fimA Ⅱ and fimA Ⅳ genotypes of P. gingivalis are highly present in patients with periodontal disease. Therefore, these two genotypes may be related to the pathogenesis and progress of periodontal disease, one of the main risk factors of periodontitis.

Prevalence of hepatitis E virus infection among blood donors in mainland China: a meta-analysis.

BACKGROUND: The risk of hepatitis E virus (HEV) infection from blood transfusion has raised increasing concern in many countries. Several transfusion-transmitted cases have been described in the United Kingdom and Japan. The objective was to investigate the prevalence of HEV infection among Chinese blood donors and analyze the potential risk of HEV infection through blood transfusion in China. STUDY DESIGN AND METHODS: Major English and Chinese research databases were used as background research for the study of locations, years, and the number of HEV infections among blood donors in China. The pooled, estimated rate of HEV infection was calculated. Subgroup analyses, for age, sex, and alanine aminotransferase (ALT) levels were performed using software for comprehensive meta-analysis. RESULTS: The pooled rates of anti-HEV IgM- and anti-HEV IgG-positive donations were 1.09% (95% confidence interval [CI], 0.95%-1.26%) and 30% (95% CI, 25%-34%), respectively. The prevalence of anti-HEV IgM was significantly higher in donors with elevated ALT (4.34%) compared with the rate in donors with normal ALT (1.35%; χ2 = 39.66, p < 0.01). The anti-HEV IgM and IgG rates were higher in the Southwest region (1.58 and 41%, respectively) compared to the rates in other regions of China (chi-square test, p < 0.05). The anti-HEV IgG rate was also significantly higher in donors 30 years and older compared with donors between 18 and 29 years of age (39% vs. 22%, respectively; χ2 = 1457.10, p < 0.01). Genetic analysis of HEV from RNA-positive donors indicated that the majority of HEV infections were Genotype 1 (19/33 = 58%), while the remaining 14 isolates were Genotype 4 (14/33 = 42%; χ2 = 0.758, p > 0.05). CONCLUSION: Qualified donations after routine blood donor screening still carry a potential risk for transmitting HEV. The major genotypes in Chinese donors in this study were Genotypes 1 and 4.

Routine screening of blood donations at Qingdao central blood bank, China, for hepatitis B virus (HBV) DNA with a real-time, multiplex nucleic acid test for HBV, hepatitis C virus, and human immunodeficiency virus Types 1 and 2.

BACKGROUND: The Roche cobas TaqScreen MPX test was used to evaluate the rate of hepatitis B surface antigen (HBsAg)-negative donations that were hepatitis B virus (HBV) DNA reactive from June 2010 to January 2011 in Qingdao, China. STUDY DESIGN AND METHODS: HBsAg-negative samples from 65,800 voluntary blood donors were tested with the cobas TaqScreen MPX test in pools of 6 on the Roche cobas s 201 blood screening platform. Samples positive for HBV DNA and negative for HBsAg were quantitated with the Roche COBAS AmpliPrep/COBAS TaqMan HBV test. In addition, serologic tests for HBsAg, hepatitis B surface antibody, anti-hepatitis B core antigen (anti-HBc), anti-hepatitis B e antigen (anti-HBe), and hepatitis B e antigen (HBe) were done using the Roche electrochemiluminescence immunoassay. RESULTS: A total of 80 nucleic acid amplification technology (NAT) test-reactive pools were identified and 59 pools (74%) resolved to a reactive sample. All samples were HBV DNA reactive and the viral load in each sample was quantitated. The viral loads of the samples ranged from less than 20 to 34,600 IU/mL; 13 samples (22%) had viral loads of more than 20 IU/mL, 27 samples (45.8%) had viral loads of less than 20 IU/mL, and 19 samples (32.2%) had undetectable viral loads. Of the 59 NAT-reactive samples, 40 (67.8%) were anti-HBc positive. Fifteen of the 59 samples could not be confirmed as NAT reactive either by an alternative NAT test or by serology. CONCLUSION: The HBV NAT yield in blood donors in Qingdao is 0.06% (38/65,800). This study confirmed the value of NAT for interdicting HBV-positive donations and preventing transfusion-transmitted HBV infections.